Ignite Creation Date:
2025-12-25 @ 12:31 AM
Ignite Modification Date:
2026-03-29 @ 3:50 AM
Study NCT ID:
NCT00544167
Status:
COMPLETED
Last Update Posted:
2013-04-01
First Post:
2007-10-15
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer
Sponsor:
SCRI Development Innovations, LLC
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
SCRI BRE 112
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |